Key Takeaways
- Comparable PBT up 22% in a transition quarter: Q4 FY22 was the first clean comparable quarter after the Nutraceuticals divestment, with retained business profit before tax growing 22% on 3.8% sales growth.
- Lantus NLEM price cut is a gross-margin pass-through: The draft ~25% price reduction will be offset by a lower purchase price from the parent under arm’s length rules, limiting bottom-line impact.
- Diabetes franchise reshuffled, not shrunk: Toujeo grew strongly, partly at Lantus’s expense, as the organization deliberately shifted focus and launched India-specific innovations like the Toujeo cartridge and Toustar pen.
- New “India for India” plan launched: Four growth pillars (Diabetes, Consumer Healthcare, Innovation, Go-to-Market) and a field-force reorganization from 8 to 3 business units are now in place, with some benefit already visible in Q4.
- What to watch next quarter: The final notified Lantus prices and any short-term inventory impact, the pace of Clexane normalization, and whether the Q4 reorganization’s efficiency gains sustain into FY24.
Lantus NLEM: The Price-Cut Mechanism
- Draft price cut disclosed: The largest SKU faces an estimated directional decrease of around 25%, though final prices are not yet notified and a debate on the calculation remains open.
- Arm’s length protection: If the price cut drops local profitability below the arm’s length range, the group compensates by reducing the purchase price, so the bottom-line impact will be limited from a gross margin perspective.
- Short-term inventory risk: A temporary impact is possible depending on the carrying inventory at the time the final price is implemented, but the structural margin is protected.
- Arm’s length is mandatory: Management stressed this is not a choice but a requirement under income tax laws, and the profitability percentage evolves each year based on benchmarks and comparisons.
Vaibhav Karandikar: “In case there is a drop in profitability below the arm's length, this would be compensated by the group. Effectively, it means the purchase price of the product will drop and the discussion will be taken with the group companies for that.”
Diabetes Portfolio: Toujeo Rises, Lantus Steps Back
- Deliberate focus shift: Lantus performance was negatively impacted because the organization placed high focus behind accelerating Toujeo; Toujeo grew very strongly and part of that growth came out of Lantus, resulting in reduced focus on Lantus production and sales.
- India-specific innovation drove Toujeo: A clear uptick in Toujeo between 2021 and 2022 followed the launch of the cartridge form (not available anywhere else in the world) and the Toustar pen, both developed for India.
- Diabetes pillar resourced: As part of the reorganization, 150–200 people were reallocated to strengthen diabetes business coverage, and the plan includes expanding the spectrum of offering across orals and injectables plus stronger disease awareness initiatives.
Rodolfo Hrosz: “Lantus performance this year was negatively impacted by a high focus of the organization behind the acceleration of Toujeo. Toujeo grew very strongly. And part of that growth came out of Lantus.”
Q4 FY22 Performance & the New Baseline
- Comparable retained-business growth: Excluding the divested Nutraceuticals business (sold September 2021), the Soframycin impact, and equalizing exceptional exports, retained business sales grew 3.8% and profit before tax grew 22% in Q4 FY22.
- Domestic retail dipped: Domestic retail showed minus 2% growth, partly due to supply issues in Targocid, one of the big brands.
- Exports surged: Export growth was 26% over the previous year in Q4 FY22.
- Gross margin improved slightly: Driven by product mix impact in the domestic segment and strengthening of the euro from the beginning of the year to date, which gave a benefit on exports.
- Clexane normalized: The brand saw a huge decline because 2021 had a COVID-driven spike; going forward, more normalized growth is expected as the COVID impact is out of the question, though a re-averaging impact from the 5-year price revision cycle is also expected.
- Full-year comparable picture: Excluding Nutraceuticals, Soframycin, and COVID-related exceptional sales in 2021, comparable sales growth was ~3.7% and comparable PBT growth was 6%.
Vaibhav Karandikar: “Q4 '22 is the first quarter where the compare -- it's largely comparable quarter. And it can -- from a comparison and a growth perspective, it is easy for us to monitor Sanofi's performance quarter-on-quarter from now on because the exceptional impact largely diminishes going forward.”
The “India for India” Strategic Plan
- Four growth pillars: Diabetes (strengthen portfolio positioning, expand oral and injectable spectrum, drive disease awareness), Consumer Healthcare (double down on Allegra investment, deepen consumer understanding, expand range from global portfolio), End-to-End Innovation (leverage global products not yet in India, pursue adjacent local innovations, explore supply localization aligned with Make in India, seek partnerships for regional reach), and Go-to-Market (customer-centric hybrid model, dedicated trade organization, transformative pilots in e-commerce and key account management).
- Organization restructured in Q4: Eight business units consolidated into three, enlarging the baskets offered to doctors and extending reach by reducing overlap; an innovation function and a trade function were added.
- Field force redeployed: The number of HCPs reached increased while keeping the number of reps constant, by reducing overlaps, and resource allocation shifted from a historical basis to an insight-driven model.
- Efficiency gains already visible: Resource mobilization and deployment efficiencies kicked in during Q4 FY22 and are expected to continue in the next quarters.
- Partnerships on the horizon: Management believes partnering with other players can extend capillarity to reach more doctors, patients, and pharmacies; both in-licensing and out-licensing are viable potential types, though no specific partnership is currently in the works.
Rodolfo Hrosz: “We called it India for India, Sanofi's India for India plan.”
Innovation & Local Manufacturing
- Innovation pipeline grounded in specific opportunities: The plan, developed in H2 2022, targets specific segments of high growth and aims to bring innovation to market in the coming quarters and years, though management cautioned that in the pharma industry this takes longer than in consumer goods.
- Local manufacturing ambition: The company sees opportunity for more local manufacturing; some parts of the imported portfolio could eventually be produced in India, improving reliability, cost, and alignment with Make in India, though specific percentage targets were not disclosed.
- Launches under the listed entity: The company plans to pursue launches under Sanofi India Limited, but declined to disclose specific products, numbers, or therapy focus.
- No upfront R&D cash required: Management emphasized they do not need to put upfront cash for global or local innovation, focusing instead on efficiency over headcount metrics.
Rodolfo Hrosz: “The plan is to bring innovation to the market. It will happen in the coming quarters and years. But it will happen in the coming years, let's put it this way. But it could not have happened immediately, in consumer goods, you would be able to decide to innovate and tomorrow already in our industry, it takes a little longer.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Operating efficiencies | Resource mobilization and deployment efficiencies to continue being visible | Next quarters (from Q1 FY24 onward) |
| Clexane normalization | More normalized growth expected as COVID impact is out of the question | From FY23 onward |
| Lantus NLEM bottom-line protection | Bottom-line impact limited; arm’s length mechanism will adjust purchase price from the group | Upon final price notification (date pending) |
| WPI price increase | Next WPI increase expected; company hopeful government notification will reflect index numbers | April 2023 |
| Innovation launches | Innovation to be brought to market under the “India for India” plan | Coming quarters and years |
| Integrated ESG reporting | First integrated report with ESG figures to be disclosed | Upcoming annual report |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue (retail business, comparable) | +3.7% YoY, excluding Nutraceuticals, Soframycin, and COVID impact; published de-growth of 2% |
| Revenue (retail business, published) | –2% YoY |
| Export growth | +26% YoY |
| Profit before tax (comparable) | +6% YoY, excluding exceptional items |
| Profit before tax (published) | –5% YoY |
| Profit before tax margin | 28% of sales, up from 22% in FY17 |
| NLEM exposure | 15% to 16% of sales; expected to rise to 40% if Lantus is included |
| Lantus draft price cut | ~25% average reduction across SKUs, per draft notification |
| Cardace expected price reduction | ~14% for plain tablets under NLEM |
| Diabetes patient coverage | Above 7 lakh patients in 2021, up from ~6.5 lakh in 2020 |
| Vitamin D3 market share | 5%, in a market of ₹800 cr growing at 3% |
| Retail business CAGR (pure) | 7.2% over the period shown |
| Full portfolio CAGR (incl. divested) | ~5% over the period shown |
| Diabetes business coverage increase | 150–200 people reallocated to strengthen diabetes coverage |